Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial.

In conclusion, although maintenance therapy with biweekly bortezomib for up to 1 year was feasible, plateau-oriented bortezomib induction therapy followed by bortezomib maintenance therapy was not adequate in newly diagnosed transplant-ineligible MM patients. PMID: 29594921 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29594921?dopt=Abstract

Source: International Journal of Hematology - March 28, 2018 Category: Hematology Authors: Isoda A, Murayama K, Ito S, Kohara Y, Iino M, Miyazawa Y, Matsumoto M, Handa H, Imai Y, Ishiguro T, Izumita W, Kitano K, Hirabayashi Y, Nakazawa H, Ishida F, Mitsumori T, Kirito K, Chou T, Murakami H, Kanshinetsu Multiple Myeloma Study Group Tags: Int J Hematol Source Type: research